Our top story this week focused on the potential for a new PET radiotracer in imaging prostate cancer. In phase II and phase III clinical trials, F-18 CTT1057 PET/CT was efficacious as a molecular imaging biomarker for the detection of prostate-specific membrane antigen (PSMA)-positive lesions. F-18 CTT1057 is being developed as part of a theranostics pair, and the goal is to expand treatment options for patients, according to the research team.
Meanwhile, our second most highly-viewed articles reported on research that found CT colonography (CTC) to be more cost-effective than multitarget stool DNA testing for colorectal cancer screening. A three-year CTC surveillance strategy for small colorectal polyps and colonoscopy referral for large polyps delivered the best overall balance of cost and clinical efficacy, according to Perry Pickhardt, MD, of the University of Wisconsin in Madison, and colleagues.
In a development that may accelerate the evaluation process and lower R&D costs, the use of animals to test PET radiotracers is being phased out. Also, serial PET/CT exams have demonstrated the value of infliximab for treating patients with refractory cardiac sarcoidosis.
Additionally, more breast lesions can be found on MRI if an apparent diffusion coefficient (ADC) cutoff is used, according to a recent study. Other popular articles highlighted topics such as the benefits of using ultralow-dose CT in osteoporosis patients and the usefulness of high-resolution ultrasound for evaluating forearm lacerations.
See below for the full list of our top stories of the week:
Erik L. Ridley
Editor in Chief
AuntMinnie.com
